Holen Sie sich die Stockscreener-App
18.93
4.53%
0.82
Schlusskurs vom Vortag:
$18.11
Offen:
$18.3
24-Stunden-Volumen:
759.37K
Relative Volume:
0.82
Marktkapitalisierung:
$2.13B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-8.8047
EPS:
-2.15
Netto-Cashflow:
$-141.24M
1W Leistung:
+7.50%
1M Leistung:
-5.49%
6M Leistung:
-3.62%
1J Leistung:
+0.96%
1-Tages-Spanne:
$17.80
$19.05
1-Wochen-Bereich:
$16.79
$19.05
52-Wochen-Spanne:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Vergleichen Sie NAMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
18.93 | 1.91B | 14.09M | -176.94M | -141.24M | -2.15 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock - Investing.com
Northern Trust Corp Takes $556,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Rating Increased to Hold at Wall Street Zen - Defense World
(NAMSW) Proactive Strategies - news.stocktradersdaily.com
Shareholders Will Probably Not Have Any Issues With NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) CEO Compensation - simplywall.st
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - GlobeNewswire
NewAmsterdam Pharma CEO to Present at William Blair, Jefferies, and Goldman Sachs Healthcare Conferences - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Recommendation of “Buy” by Analysts - Defense World
(NAMS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market By Investing.com - Investing.com South Africa
NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market - Investing.com Canada
35,657 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by BNP Paribas Financial Markets - Defense World
Financial Contrast: NewAmsterdam Pharma (NAMS) versus Its Rivals - Defense World
(NAMSW) Investment Analysis - news.stocktradersdaily.com
The Manufacturers Life Insurance Company Purchases New Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Tower Research Capital LLC TRC Sells 6,485 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know - MSN
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - GlobeNewswire
NewAmsterdam Pharma Showcases Non-Statin CVD Pipeline at Major RBC Healthcare Conference - Stock Titan
(NAMS) Proactive Strategies - news.stocktradersdaily.com
Analysts Have Been Trimming Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target After Its Latest Report - simplywall.st
Barclays PLC Buys 9,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Needham & Company LLC Issues Pessimistic Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World
NewAmsterdam Pharma Reports Q1 2025 Financial Results - TipRanks
NewAmsterdam Pharma Q1 Net Loss Narrows, Revenue Rises - marketscreener.com
NewAmsterdam Pharma Company NV reports results for the quarter ended March 31Earnings Summary - TradingView
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - GlobeNewswire
Ratios Revealed: Decoding NewAmsterdam Pharma Company NV (NAMS)’s Financial Health - DWinneX
Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $2.98M, vs. FactSet Est of $1.6M - marketscreener.com
Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $3M, vs. FactSet Est of $1.6M - marketscreener.com
NewAmsterdam Pharma Q1 2025 Financial Results and Corporate Update - TradingView
Envestnet Asset Management Inc. Sells 8,738 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Announces Late-Breaking Data from - GlobeNewswire
NewAmsterdam Pharma (NAMS) Reveals Promising Phase 3 Study Results for Obicetrapib | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Presents Promising Phase 3 Trial Data - TipRanks
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 - marketscreener.com
Trend Tracker for (NAMS) - news.stocktradersdaily.com
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33 - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Expands Clinical Team with 11 New Hires, Awards $4M in Equity Grants - Stock Titan
Examining NewAmsterdam Pharma Company NV (NAMS) stock is warranted - uspostnews.com
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress - GlobeNewswire
Major Breakthrough: NewAmsterdam Reveals Multiple Phase 3 Trial Results for Novel Heart Drug - Stock Titan
Geode Capital Management LLC Raises Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
Legal & General Group Plc Acquires 4,556 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Invesco Ltd. Invests $3.87 Million in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by JPMorgan Chase & Co. - Defense World
A closer look at NewAmsterdam Pharma Company NV (NAMS)’s stock price trends - uspostnews.com
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):